Literature DB >> 360197

Treatment of congestive cardiomyopathy.

W H Abelmann.   

Abstract

Although the majority of patients with cardiomyopathy are in the category of primary or idiopathic cardiomyopathy, for which therapy is symptomatic and non-specific, there are a number of secondary forms of cardiomyopathy for which specific therapy is available, thus giving impetus to prompt and accurate diagnosis. Among inflammatory lesions, brucellosis, psittacosis and toxoplasmosis are examples. Treatable metabolic causes include thyrotoxicosis and thiamine deficiency, the latter as well as calorie-protein malnutrition are also preventable. There is presumptive evidence that the cardiomyopathy of haemochromatosis is benefited by repeated phlebotomies. Symptomatic relief of obstructive cardiomyopathy is achieved by beta-adrenergic blockade, although resection of obstructing myocardium still has a place. The therapeutic approach to the vast majority of cases of congestive cardiomyopathy is non-specific, comprising controlled activity, sodium restriction, digitalis and diuretics. Vasodilators and, occasionally, beta-adrenergic blockade may be beneficial. Pacemakers may be life-saving, whereas the place of anti-arrhythmics remains uncertain. Transplantation warrants further application. Valve replacement has little to offer. Primary prevention, comprising balanced nutrition, vaccines and genetic counselling, merits wider application. In individuals at risk or already afflicted, programmes of secondary prevention should include good nutrition, abstinence from alcohol and protection from drugs and toxins.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 360197      PMCID: PMC2425121          DOI: 10.1136/pgmj.54.633.477

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  25 in total

1.  EFFECTS OF MUSCULAR ACTIVITY UPON THE ACUTE MYOCARDITIS OF C3H MICE INFECTED WITH TRYPANOSOMA CRUZI.

Authors:  S H ELSON; W H ABELMANN
Journal:  Am Heart J       Date:  1965-05       Impact factor: 4.749

2.  Heart disease and filtrable viruses.

Authors:  J M PEARCE
Journal:  Circulation       Date:  1960-03       Impact factor: 29.690

3.  The induction of gross myocardial lesions by a Coxsackie (pleurodynia) virus and cortisone.

Authors:  E D KILBOURNE; C B WILSON; D PERRIER
Journal:  J Clin Invest       Date:  1956-04       Impact factor: 14.808

4.  Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure.

Authors:  E Mikulic; J N Cohn; J A Franciosa
Journal:  Circulation       Date:  1977-10       Impact factor: 29.690

5.  Prenatal diagnosis of Duchenne's muscular dystrophy.

Authors:  M J Mahoney; F P Haseltine; J C Hobbins; B Q Banker; C T Caskey; M S Golbus
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

6.  Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  D W Duhme; D J Greenblatt; J Koch-Weser
Journal:  Ann Intern Med       Date:  1974-04       Impact factor: 25.391

7.  Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure.

Authors:  H S Loeb; J Bredakis; R M Gunner
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

8.  Effect of the vasodilator trimazosin versus placebo on exercise performance in chronic left ventricular failure.

Authors:  W S Aronow; R S Greenfield; H Alimadadian; D T Danahy
Journal:  Am J Cardiol       Date:  1977-11       Impact factor: 2.778

9.  Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.

Authors:  B Massie; K Chatterjee; J Werner; B Greenberg; R Hart; W W Parmley
Journal:  Am J Cardiol       Date:  1977-11       Impact factor: 2.778

10.  Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients.

Authors:  J A Franciosa; G Pierpont; J N Cohn
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.